| Trial ID: | L2685 |
| Source ID: | NCT01654380
|
| Associated Drug: |
Ly2605541
|
| Title: |
A Study of LY2605541 Versus Insulin Glargine on Blood Sugar
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01654380/results
|
| Conditions: |
Healthy Volunteers|Diabetes Mellitus, Type 1
|
| Interventions: |
DRUG: LY2605541|OTHER: Insulin glargine
|
| Outcome Measures: |
Primary: Part B: Glucodynamics: Endogenous Glucose Output, The percent suppression from baseline in endogenous glucose production (EGP) is presented. Percent EGP change from baseline was calculated by (1-\[last 2 hours of EGP/basal EGP\])\*100. The duration of the clamp procedure was 10 hours for the LY2605541 74.1 mU/min dose in Part B. The duration of the clamp procedures performed at the 15.3 mU/min LY2605541 dose and both of the insulin glargine doses was 8 hours., Baseline, up to 10 hours (duration of the euglycemic glucose clamp)|Part B: Glycodynamics: Glucose Disposal, The fold change from baseline in glucose disappearance rate (GDR) is presented. The fold GDR increase from baseline was calculated by last 2 hours of GDR/basal GDR. The duration of the clamp procedure was 10 hours for the LY2605541 74.1 mU/min dose in Part B. The duration of the clamp procedures performed at the 15.3 mU/min LY2605541 dose and both of the insulin glargine doses was 8 hours., Baseline, up to 10 hours (duration of the euglycemic glucose clamp)|Part B: Glycodynamics: Maximum Rate of Glucose Disposal, The maximum rate of glucose disposal (Rdmax) is presented. The duration of the clamp procedure was 10 hours for the LY2605541 74.1 mU/min dose in Part B. The duration of the clamp procedures performed at the 15.3 mU/min LY2605541 dose and both of the insulin glargine doses was 8 hours., Baseline, up to 10 hours (duration of the euglycemic glucose clamp) |
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
MALE
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
22
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER
|
| Start Date: |
2012-07
|
| Completion Date: |
2013-10
|
| Results First Posted: |
2019-03-08
|
| Last Update Posted: |
2019-03-08
|
| Locations: |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01654380
|
